SCHEMBL20967258

SCHEMBL20967258

CC(C)(C)OC(=O)N1CCC(n2cc(C(N)=O)nn2)CC1

nearest known ligand 0.50

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 11/20 0.47
DDB1 Q16531 1/20 0.45
CRBN Q96SW2 1/20 0.45
IRAK4 Q9NWZ3 1/20 0.44
CTSD P07339 1/20 0.43
CTSE P14091 1/20 0.43
BACE1 P56817 1/20 0.43
HTT P42858 1/20 0.43
ATM Q13315 1/20 0.43
PARP1 P09874 1/20 0.42
KDM4E B2RXH2 1/20 0.42
MAPT P10636 1/20 0.42
THRB P10828 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14692527 0.89 GPR119 (0.46) GPR119DDB1CRBNHTTATM
SCHEMBL23911654 0.87 KDM4E (0.47) GPR119DDB1CRBNIRAK4CTSD
SCHEMBL23911653 0.84 KDM5C (0.49) GPR119DDB1CRBNKDM4E
SCHEMBL18376153 0.84 GPR119 (0.47) GPR119DDB1CRBNHTTATM
SCHEMBL16716871 0.82 GPR119 (0.46) GPR119DDB1CRBNCTSDCTSE
SCHEMBL18367623 0.82 GPR119 (0.46) GPR119DDB1CRBNHTTATM
SCHEMBL22875377 0.82 HTT (0.45) GPR119DDB1CRBNCTSDCTSE
SCHEMBL22730550 0.81 DDB1 (0.48) GPR119DDB1CRBNHTTATM
SCHEMBL21410874 0.81 HTT (0.46) GPR119DDB1CRBNHTTATM
SCHEMBL6071289 0.81 DDB1 (0.45) GPR119DDB1CRBNCTSDCTSE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210317113-A1 1,2,3-TRIAZOLE DERIVATIVES AND USES THEREOF Alxerion Biotech LLC 2021-10-14 US disclosed
US-10703748-B2 Diazanaphthalen-3-yl carboxamides and preparation and use thereof SAMUMED, LLC (US) 2020-07-07 US disclosed
US-20190127370-A1 DIAZANAPHTHALEN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF VICKERS-SPLICE CO-INVESTMENT LLC (KY) 2019-05-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210317113-A1 1,2,3-TRIAZOLE DERIVATIVES AND USES THEREOF CYP3A43, CYP51A1, CYP11B2 GPR119 4605/4885DDB1 3333/4885CRBN 2486/4885
US-20190127370-A1 DIAZANAPHTHALEN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF DYRK1A, DKK1, WNT1 GPR119 830/4885DDB1 495/4885CRBN 548/4885
US-10703748-B2 Diazanaphthalen-3-yl carboxamides and preparation and use thereof DYRK1A, DKK1, WNT1 GPR119 830/4885DDB1 495/4885CRBN 548/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.